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Streptococcus pneumoniae genomes encode three sialidases, NanA, NanB and
NanC, which are key virulence factors that remove sialic acids from various
glycoconjugates. The enzymes have potential as drug targets and also as vaccine
candidates. The 115 kDa NanA is the largest of the three sialidases and is
anchored to the bacterial membrane. Although recombinantly expressed full-
length NanA was soluble, it failed to crystallize; therefore, a 56.5 kDa domain
that retained full enzyme activity was subcloned. The puriﬁed enzyme was
crystallized in 0.1 M MES pH 6.5, 30%(w/v) PEG 4000 using the sitting-drop
vapour-diffusion method. Data were collected at 100 K to 2.5 A ˚ resolution from
a crystal grown in the presence of the inhibitor 2-deoxy-2,3-dehydro-N-acetyl
neuraminic acid. The crystal belongs to space group P212121, with unit-cell
parameters a = 49.2, b= 95.6, c= 226.6 A ˚ . The structure was solved by molecular
replacement and reﬁned to ﬁnal R and Rfree factors of 0.246 and 0.298,
respectively.
1. Introduction
Streptococcus pneumoniae is a major human pathogen that is
responsible for respiratory-tract infections, septicaemia, otitis media
and meningitis. Current broad-spectrum antibiotic treatments for
S. pneumoniae are increasingly unsuccessful owing to the emergence
of drug-resistant strains (Thornsberry et al., 1999). There are multi-
valent capsular polysaccharide vaccines available for pneumococcal
disease, but their efﬁcacy in certain high-risk groups has been ques-
tioned (Siber, 1994). More recently, a conjugate polysaccharide
vaccine has been introduced successfully (Prevenar, Wyeth), but
there are concerns about how readily it can be introduced globally
and about its continuing efﬁcacy. A search is therefore on for new
drug and vaccine candidates for pneumococcal diseases. Several
virulence factors may contribute to colonization and early infection
processes (Jedrzejas, 2001). Sialidases are one key virulence factor as
they remove sialic acid from host cell-surface glycans, probably
unmasking certain receptors to facilitate bacterial adherence and
colonization (Paton et al., 1993). To date, all S. pneumoniae clinical
isolates investigated have had prominent sialidase activities. Up to
three distinct sialidases, NanA (Camara et al., 1994), NanB (Berry et
al., 1996) and NanC, are encoded in S. pneumoniae genomes, with a
recent study revealing NanA to be present in all clinical strains
(Pettigrew et al., 2006). Gene-knockout studies in mouse models have
shown that NanA and NanB are essential for S. pneumoniae infection
(Manco et al., 2006).
In this paper, we report the 2.5 A ˚ resolution X-ray crystallographic
structure of the catalytic domain of S. pneumoniae NanA and its
complex with the inhibitor 2-deoxy-2,3-dehydro-N-acetyl neuraminic
acid (Neu5Ac2en). This provides a framework for the structure-
based design of speciﬁc inhibitors of pneumococcal sialidases as
potential therapeutic agents.2. Experimental
Full-length NanA could be recombinantly expressed and puriﬁed, but
failed to crystallize. Limited proteoloysis using trypsin, followed by
mass spectrometry of the cleavage products, identiﬁed a stable sub-
domain, which we designate CNanA, that spans residues 319–822 and
encompasses a domain that retains the enzyme activity of the full-
length NanA. The S. pneumoniae nanA gene in a pQE30 vector was
used as a template in polymerase chain reaction (PCR) with the
following primers: 50-ACCTCCATGGAAGGAGCGGCTTTAACA-
GAGA-30 and 50-GGGCCTCGAGTTAGACCAATACTTCTGAG-
TCG-30 (NcoI and XhoI restriction sites in bold). The PCR product
was then ligated into the pHISTEV vector, containing six histidines
and a tobacco etch virus (TEV) cleavage peptide at the N-terminus,
and plasmid DNA was extracted using a Mini-Prep Kit (Promega).
The plasmid was transformed into Escherichia coli BL21 (DE3)
expression strain (Novagen) for protein expression. The transformed
E. coli was inoculated into Luria–Bertani (LB) medium with
100 mgm l
 1 kanamycin at 310 K. 0.5 mM isopropyl  -d-thiogalacto-
pyranoside (IPTG) was added to induce CNanA expression when the
optical density at 600 nm (OD600) of the cultures reached 0.6. Cell
culture continued at 310 K for 3 h before harvesting by centrifugation
at 4500g for 30 min at 277 K. The harvested cell pellets were resus-
pended in 0.1 M phosphate pH 7.4, 10 mM imidazole and sonicated
with 5   30 s bursts. Protease-inhibitor cocktail tablets (one tablet
per 25 ml extract; Roche Diagnostics) and DNAase (Sigma; ﬁnal
concentration 20 mgm l
 1) were then added. The crude cell extract
was centrifuged at 43 000g for 20 min at 277 K to remove the cell
debris and the supernatant was ﬁltered with a syringe-driven ﬁlter
(0.45 mm) before starting protein puriﬁcation. Soluble cell extract was
loaded onto a 5 ml nickel column (GE Healthcare) and the bound
protein was eluted with 300 mM imidazole in 0.1 M phosphate buffer
pH 7.4. Protein purity was assessed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) and matrix-assisted
laser desorption time-of-ﬂight mass spectrometry (MALDI–TOF).
Relatively high-purity target protein was pooled for gel ﬁltration
using a 120 ml Sephacryl-200 column (GE Healthcare). The puriﬁed
CNanA was dialysed against 0.1 M Tris–HCl pH 8.0, 150 mM NaCl
overnight before concentration and storage.
Puriﬁed protein was concentrated to 10.9 mg ml
 1 for crystal-
lization experiments using the sitting-drop vapour-diffusion method
at 290 K with the commercial kits Classics (Jena Bioscience), JCSG,
Nextal PEGs and Nextal pH Clear (Qiagen). Crystalline materials
were observed after 3 d from condition No. 32 of Nextal PEGs [0.1 M
MES pH 6.5, 25%(w/v) PEG 4000]. This condition was selected for
crystallization optimization with crystallization drops made up of
equal amounts of protein solution and reservoir solution (2 ml each).
The best condition for CNanA crystallization was 0.1 M MES pH 6.5,
30%(w/v) PEG 4000. Crystals appeared in about 2 d and reached
their maximum size after one week. The crystals have the remarkable
habit of a square hollow tube (Fig. 1). Crystals of the Neu5Ac2en
complex structure were grown in the presence of 10 mM Neu5Ac2en.
Crystals were cryoprotected by transfer for a few minutes into a
solution of the crystallization buffer with 20%(v/v) glycerol before
data collection at 100 K. Data were collected in-house (Rigaku-MSC
MicroMax-007 HF X-ray generator and Saturn 944+ CCD detector).
HKL-2000 (Otwinowski & Minor, 1997) was used for data processing
and scaling and data-collection statistics are shown in Table 1. The
catalytic domain of Clostridium perfringens sialidase NanI (Newstead
et al., 2008; PDB code 2bf6) was used to solve the CNanA structure
by molecular replacement using Phaser (McCoy et al., 2007) in the
CCP4 suite (Collaborative Computational Project, Number 4, 1994).
The asymmetric unit contains two CNanA molecules. The automated
model-building wizard of the Phenix package (Adams et al., 2002) was
used to build the initial structure using the 2.5 A ˚ resolution
Neu5Ac2en complex data. This procedure built 85% of the residues
with an R and Rfree of 0.29 and 0.35, respectively. Coot (Emsley &
Cowtan, 2004) and REFMAC5 (Murshudov et al., 1997) were used to
reﬁne and build the ﬁnal model, which was validated with MolProbity
(Lovell et al., 2003). Reﬁnement statistics are summarized in Table 1.
The ﬁrst 20 amino acids, including the six-histidine tag and TEV
cleavage peptide, and the last 20 amino acids are not visible in the
electron-density maps; the ﬁnal model consists of residues 322–791.
Molecule A is generally well ordered, whereas molecule B shows
disorder in its N- and C-terminal regions. Both monomers have
Neu5Ac2en bound.
3. Results and discussion
The structure of CNanA shows the canonical six-bladed  -propeller
fold common to all sialidases (Fig. 2). In common with the catalytic
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Table 1
Crystallographic summary.
Values in parentheses are for the highest resolution shell.
Space group P212121
Unit-cell parameters (A ˚ ) a = 49.2, b = 95.6, c = 226.6
Maximum resolution (A ˚ ) 2.5 (2.54–2.50)
Unique reﬂections 36773
Completeness 95.2 (71.2)
I/ (I) 27.3 (4.6)
Mosaicity ( ) 0.64
Redundancy 2.9 (2.5)
Rmerge† 0.063 (0.248)
VM (A ˚ 3 Da
 1) 2.36
Reﬁnement
Protein atoms 7442
Other atoms 40 (Neu5Ac2en), 124 waters, 1 Cl
 
Resolution range (A ˚ ) 30–2.5
Rcryst‡ 0.246
Rfree‡ 0.298
Mean temperature factor (A ˚ 2)
Protein, monomer A/B 29/45
Neu5Ac2en, monomer A/B 25/45
Waters 25
R.m.s.d. bond lengths (A ˚ ) 0.007
R.m.s.d. bond angles ( ) 1.145
Ramachandran favoured/outliers (%) 90.5/3.7
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.‡ Rcryst and Rfree = ð
P   jFoj 
jFcj
   Þ=ð
P
jFojÞ; Rfree was calculated for a 5% set of reﬂections excluded from the
reﬁnement.
Figure 1
Crystals of CNanA. The scale bar represents 0.5 mm.domains of C. perfringens NanI (Newstead et al., 2008) and leech
sialidase (PDB code 1sli; Luo et al., 1998), CNanA has a small
domain, residues 436–535, inserted between the second and third
strands of the second sheet. CNanA and NanI share 41% sequence
identity and the r.m.s.d. between 413 C
  atoms is 1.26 A ˚ . The two
monomers in the asymmetric unit are related by a noncrystallo-
graphic twofold axis, superimpose with an r.m.s.d. of 0.39 A ˚ over 470
C
  atoms and bury  1200 A ˚ 2 of surface at their dimer interface. The
calibrated gel ﬁltration suggests that CNanA is
predominantly a monomer in solution; however,
it is possible that full-length NanA may be a
dimer on the bacterial surface. The active site
contains the usual catalytic residues common to
all sialidases (Taylor, 1996): three arginines
(Arg347, Arg663, Arg721) that interact with the
carboxylate group of sialic acid, a nucleophilic
tyrosine (Tyr752) that is proposed to form a
covalent intermediate (Watts et al., 2006; New-
stead et al., 2008) and its associated glutamic acid
(Glu647), an aspartic acid (Asp372) that acts as
an acid/base and a hydrophobic pocket that
accommodates the acetamidomethyl group of
sialic acid. In common with other bacterial siali-
dases, the hydroxyl group at C4 on Neu5Ac2en
interacts with an arginine (Arg366) and an
aspartic acid (Asp417). The O8 and O9 hydroxyls
of the ligand’s glycerol group interact with Tyr590
and Gln602, respectively. The topology of the
surface of CNanA around the location of the
aglycon is ﬂat and open, in line with the
promiscuity shown by NanA towards  (2,3),
 (2,6) and  (2,8) linkages (unpublished data) and
in contrast to leech sialidase and Trypanosoma
cruzi trans-sialidase, which show speciﬁcity for
 (2,3)-linked sialic acids (Amaya et al., 2003).
Two inhibitors of the inﬂuenza virus neuramini-
dase, zanamivir and oseltamivir, are currently
licensed as treatments for inﬂuenza and both
were developed based on the framework of
Neu5Ac2en. The study reported here lays the
groundwork for the potential elaboration of the
core of Neu5Ac2en, particularly around the
acetamido and glycerol moieties, in order to
develop speciﬁc inhibitors of the pneumococcal
sialidases.
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